BenevolentAI (OTC:BAIVF) has announced a strategic overhaul to refocus on its original mission of integrating artificial intelligence with drug development.
The London-based tech and life sciences company aims to strengthen its core technologies and improve efficiency, ensuring financial stability until 2027.
As part of these changes, Benevolent is considering delisting from Euronext Amsterdam to reduce costs and streamline operations.
At the same time, it plans to reshape its workforce and has already implemented cost-saving measures to create a leaner structure.
These adjustments are intended to enhance operational agility and redirect resources to its core activities in AI-driven drug discovery.
BenevolentAI (OTC:BAIVF) will also transform its technology into modular products tailored to biopharma partners' needs, enabling faster integration and customised applications.
Future efforts will focus on reducing financial risks by partnering on early-stage drug assets sooner.
"Our strategic direction builds on our strengths, empowering the biopharma industry with cutting-edge AI technologies backed by our compelling industry and patient proof points," said chairman Kenneth Mulvany.
“Since rejoining the board, I have initiated a new roadmap that returns our technologies to more adaptable, standalone products tailored to meet our partners’ drug development needs. This ensures quicker integration and versatility across various phases of the development process.
“Reshaping BenevolentAI (OTC:BAIVF) involved tough but necessary decisions to strategically allocate finances, enhance efficiency, refocus business development, and invest in targeted product initiatives.
"These challenging decisions are vital to enable sustainable growth and deliver value to our shareholders, partners, and the patients we ultimately serve.”
BenevolentAI’s achievements include contributing to an FDA-approved drug, advancing clinical candidates, and meeting milestones in its AstraZeneca collaboration.